THRU ONLINE FILING

November 20, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that as part of the Company's operational strategy and to reduce number of manufacturing units and in order to minimize operational and other costs, the Company has decided to close the manufacturing operations of its Mahad (Maharashtra) drug intermediates manufacturing unit and sell/transfer leasehold land property of the said manufacturing unit being Plot Nos. C-89 to C-95, MIDC, Mahad (Maharashtra) along with all the rights, title and interest in the said leasehold land together with old factory buildings, structures and sheds standing on the said leasehold land to M/s. ICMC Corporation Ltd. for a consideration of Rs. 16.90 crores subject to necessary approvals.

The closure of this manufacturing unit will not have any impact on Company's business and financials. The drug intermediates manufactured at the said manufacturing unit is shifted to other manufacturing units.

The other required details of this transaction are as under:

1.	Manufacturing unit /facility to be closed and lease hold land and buildings/structures standing on the said manufacturing unit is proposed to be sold and transferred	The Company is closing the manufacturing operations of the Company's drug intermediates manufacturing unit being and situated at leasehold Plot Nos.C-89 to C-95, MIDC, Mahad 402309 (Maharashtra) and sell/transfer the lease hold rights of the said leasehold land admeasuring about 25,138 sq mtrs toghether with the old factory buildings/structures/sheds etc. admeasuring about 11,913 sq mtrs standing thereon. Plant and machineries situated at this manufacturing unit will be transferred to other manufacturing units of the Company. The drug intermediates being manufactured at this manufacturing unit are already transferred for manufacturing at other manufacturing units of the Company.

2.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The manufacturing unit proposed to be closed was primarily manufacturing drug intermediates mostly captively used for manufacturing of the Company's APIs. The drug intermediates manufactured at this manufacturing unit are transferred for manufacturing at the other manufacturing units. The current written down value of the leasehold land and old buildings / structures/sheds comprising of this manufacturing unit is Rs.13.21 crores. The closure of this manufacturing unit and sale of lease hold land and old buildings/structures/sheds standing thereon will not have any impact on the Company's business and financials.
3.	Date on which the agreement for sale has been entered into	The MOU is entered into with the buyer today and the final transaction deed will be entered into in due course of time subject to necessary approvals and consents.
4.	The expected date of completion of sale	On or before 31st March, 2027 or such other date as may be mutually agreed subject to the necessary consent from MIDC for the transfer of the leasehold rights on the land.
5.	Consideration receivable from such sale	Rs. 16.90 crores for sale/transfer of lease hold rights on the leasehold land along with old factory buildings, structures and sheds standing thereon.
6.	Brief details of buyers and whether the buyer belong to the promoter/ promoter group/ group companies. If yes, details thereof;	M/s. ICMC Corporation Ltd. is a company incorporated under the provisions of the Companies Act, 1956. It is engaged in the business of development, manufacture, distribution and sale of micro nutrients fertilizers. M/s. ICMC Corporation Ltd. does not belong to the promoter/ promoter group of the Company and is not a related party.

7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	This transaction does not fall within the purview of related party transactions.
8.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	This transaction is outside the scheme of arrangement and is in compliance with the provisions of Regulation 37A of SEBI (LODR) Regulations.
9.	Name of the entity(ies) forming part of the slump sale, details in brief such as size, turnover etc.;	Please see information disclosed in serial nos. 1-5 above.
10.	Area of business of the entity(ies)	The Company is engaged in development, manufacturing, marketing and distribution of pharmaceuticals. M/s. ICMC Corporation Ltd. is engaged in the business of development, manufacture, distribution and sale of micro nutrients fertilizers.
11.	Rationale for slump sale	Ongoing initiative of optimization of manufacturing facilities and reducing number of smaller manufacturing unit.
12.	In case of cash consideration – amount or otherwise share exchange ratio;	Consideration of Rs.16.90 crores payable by bank transfers.
13.	Brief details of change in shareholding pattern (if any) of listed entity	There will not be any change in the shareholding pattern of the Company due to the closure and sale of the leasehold land and factory buildings/structures/sheds comprising of this manufacturing facility.

Thanking you

Yours faithfully

For Ipca Laboratories Limited

HARISH PANDURANG KAMATH

Digitally signed by HARISH PANDURANG KAMATH
DN: c=IN, postalCode=400063, st=MAHARASHTRA, street=4204, TOWER B, OBEROI ESQUIRE, YASHODHAM, MOHAN GOKHALE ROAD ,MUMBAI SUBURBAN,GOREGAON (EAST), 400063, l=MUMBAI SUBURBAN, o=Personal, serialNumber=72050fb9fadcbc5de404685117b835570295784c7617d9fdcee2a3887d6b4809, pseudonym=cfed4e638b643120a1780871ed0cb04, 2.5.4.20=9ab568e57390d9202997da5b90516430bfd7e352b111402af42d207e32e25c6, email=HARISH.KAMATH@IPCA.COM, cn=HARISH PANDURANG KAMATH
Date: 2020.11.20 13:54:45 +05'30'

Harish Kamath
Corporate Counsel & Company Secretary